Monday 26 September 2016

State urged to boost pharma's growth bid

Published 23/09/2016 | 02:30

Jean Delaney, PwC Ireland pharma leader, Mary Mitchell O’Connor and Johnathon Marshall, PwC UK, yesterday
Jean Delaney, PwC Ireland pharma leader, Mary Mitchell O’Connor and Johnathon Marshall, PwC UK, yesterday

Ireland has been urged to invest in science-based subject to ensure the biopharmaceutical industry reaches its full potential over the coming years.

  • Go To

New research from the Department of Jobs says the pharmaceutical industry is worth €30bn a year in exports and has the potential to deliver 8,000 jobs over the next three years.

To reach these targets the State must invest heavily in talent, competitiveness and innovation, Irish Pharmaceutical Healthcare Association chief executive Oliver O'Connor said.

"We we are calling on both governments, North and South, to commit to developing the talent base across the island in order to meet future demands, grow both Ireland and Northern Ireland's competitiveness globally, and provide greater support for clinical trials, IT investment and key specialists," Mr O'Connor said.

He was speaking at the 2016 BioPharma Ambition Plenary Session in Dublin Castle yesterday. The conference brought leaders from the US food and drug administration and other leading researchers.

Johnathon Marshall, PwC UK pharma leader, led the panel session on 'From lab to bedside - the convergence of manufacturing and care' noting that pharma needs to go further on embedding digital and embrace new ways of manufacturing.

The session comes after a major pharma announcement from GE Healthcare. On Monday GE announced it would be shipping in four pre-fabricated factories as part of €150m project in Ireland.

Irish Independent

Read More

Promoted articles

Editors Choice

Also in Business